Risk Factors Update Summary
- Accumulated deficit increased from $460 million to $484 million, with losses of $59.9 million in 2022 and $39.7 million in 2023.
- Planned operating expenses funded into Q3 2025, with net operating losses expected for several years.
- Headcount reduced by 29% in May 2023 restructuring, aligning resources for key clinical data readouts.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1463361&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.